Genmab A/S (NASDAQ:GMAB) Upgraded by Guggenheim to Buy Rating

Key Points

• Genmab A/S has been upgraded from a "neutral" rating to a "buy" rating by Guggenheim, with a price target of $43.00, suggesting a potential upside of 50.35% from its current price.
• Despite Guggenheim's upgrade, Zacks Research has downgraded Genmab from a "strong-buy" to a "hold" rating, indicating mixed analyst sentiment surrounding the stock.
• In its latest earnings report, Genmab A/S exceeded analysts' expectations by reporting $0.54 earnings per share, surpassing the consensus estimate of $0.39.

Genmab A/S (NASDAQ:GMAB - Get Free Report) was upgraded by equities researchers at Guggenheim from a "neutral" rating to a "buy" rating in a research report issued on Tuesday,Finviz reports. The brokerage currently has a $43.00 price target on the stock. Guggenheim's price target indicates a potential upside of 50.35% from the company's current price.

GMAB has been the subject of several other reports. Zacks Research cut shares of Genmab A/S from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. HC Wainwright boosted their price objective on shares of Genmab A/S from $35.00 to $36.00 and gave the company a "buy" rating in a report on Friday, August 15th. Wall Street Zen raised shares of Genmab A/S from a "hold" rating to a "buy" rating in a report on Monday, July 28th. Finally, Truist Financial boosted their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $40.00.

Genmab A/S Stock Performance

Shares of GMAB opened at $28.60 on Tuesday. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $28.75. The firm's 50-day simple moving average is $24.38 and its two-hundred day simple moving average is $21.83. The stock has a market cap of $18.35 billion, a PE ratio of 14.37, a price-to-earnings-growth ratio of 1.65 and a beta of 0.93.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The business had revenue of $925.00 million during the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. Equities research analysts predict that Genmab A/S will post 1.45 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Orbis Allan Gray Ltd boosted its position in shares of Genmab A/S by 38.7% during the second quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company's stock worth $163,635,000 after acquiring an additional 2,209,659 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of Genmab A/S by 152.3% during the second quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company's stock worth $71,367,000 after acquiring an additional 2,084,966 shares during the last quarter. First Trust Advisors LP boosted its position in shares of Genmab A/S by 3.5% during the second quarter. First Trust Advisors LP now owns 1,770,310 shares of the company's stock worth $36,575,000 after acquiring an additional 60,504 shares during the last quarter. Brandywine Global Investment Management LLC boosted its position in shares of Genmab A/S by 1.6% during the second quarter. Brandywine Global Investment Management LLC now owns 1,744,769 shares of the company's stock worth $36,047,000 after acquiring an additional 27,372 shares during the last quarter. Finally, Cubist Systematic Strategies LLC boosted its position in shares of Genmab A/S by 112.4% during the first quarter. Cubist Systematic Strategies LLC now owns 1,258,143 shares of the company's stock worth $24,634,000 after acquiring an additional 665,893 shares during the last quarter. Institutional investors own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.